Skip Navigation

Annals of Oncology 2009 20(7):1151; doi:10.1093/annonc/mdp339
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

in this issue

in this issue

The first 10% of the full text of this article appears below.


   Predicting DFS in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer
 
Preoperative treatment is an established therapy for patients with operable breast cancer for whom a reduction of primary tumor size is required in order to allow breast conservation. Preoperative chemotherapy might be beneficial in several ways in addition to allowing breast-conserving surgery in some of the patients. However, limited data are available on factors which . . . [Full Text of this Article]


   Prognostic significance of circulating tumor cells in metastatic colorectal cancer (mCRC)
 

   Docetaxel plus oblimersen in patients with castration-resistant prostate cancer
 

   FDG–PET for assessment of early treatment response in patients with advanced Hodgkin's lymphoma
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer
M. Colleoni, V. Bagnardi, N. Rotmensz, S. Dellapasqua, G. Viale, G. Pruneri, P. Veronesi, R. Torrisi, A. Luini, M. Intra, V. Galimberti, E. Montagna, and A. Goldhirsch
Ann Oncol 2009 20: 1178-1184. [Abstract] [Full Text]  

Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer
S. J. Cohen, C. J. A. Punt, N. Iannotti, B. H. Saidman, K. D. Sabbath, N. Y. Gabrail, J. Picus, M. A. Morse, E. Mitchell, M. C. Miller, G. V. Doyle, H. Tissing, L. W. M. M. Terstappen, and N. J. Meropol
Ann Oncol 2009 20: 1223-1229. [Abstract] [Full Text]  

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
C. N. Sternberg, H. Dumez, H. Van Poppel, I. Skoneczna, A. Sella, G. Daugaard, T. Gil, J. Graham, P. Carpentier, F. Calabro, L. Collette, D. Lacombe, and for the EORTC Genitourinary Tract Cancer Group
Ann Oncol 2009 20: 1264-1269. [Abstract] [Full Text]  

FDG–PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value
J. Markova, C. Kobe, M. Skopalova, K. Klaskova, K. Dedeckova, A. Plütschow, H. T. Eich, M. Dietlein, A. Engert, and T. Kozak
Ann Oncol 2009 20: 1270-1274. [Abstract] [Full Text]